SUNDRUG (9989) FY2026 Q3 Earnings Report

Quick View

Executive Summary

For the cumulative Q3 of the fiscal year ending March 2026, Sundrug maintained increases in revenue and earnings, although net income growth fell below operating income growth. Revenue was ¥635.71B (+5.3% YoY), operating income was ¥36.54B (+4.9%), ordinary income was ¥36.20B (+5.4%), and net income was ¥24.23B (+1.7%). Revenue growth was driven by high growth in the Discount Store Business in addition to the core Drugstore Business, while the slowdown in net income growth was primarily attributable to an increase in the effective tax rate.

Factors Affecting Earnings

【Revenue】Revenue was ¥635.71B (+5.3% YoY). By segment, the Drugstore Business generated ¥361.12B (56.8% of the total, +4.0%), while the Discount Store Business generated ¥274.59B (43.2% of the total, +7.1%), with the Discount Store Business posting the higher growth rate.

【Profit and Loss】Operating income was ¥36.54B (+4.9%), and ordinary income was ¥36.20B (+5.4%), indicating a generally stable earnings structure from the operating level through the ordinary income level. Extraordinary items resulted in a net loss of ¥0.24B (extraordinary gains of ¥0.19B and extraordinary losses of ¥0.43B, including impairment losses of ¥0.12B and losses on disposal of property, plant and equipment of ¥0.16B), with a limited impact. Profit before tax increased by +5.8% YoY, but net income increased by only +1.7% as the effective tax rate rose to 32.6%. The segment profit margin for the Drugstore Business declined from 6.09% in the previous year to 5.89%, while that of the Discount Store Business improved from 5.33% to 5.55%, indicating diverging performance between the businesses beneath the overall increase in revenue and earnings. In conclusion, the Company achieved increases in revenue and earnings.

Segment Analysis

The Drugstore Business reported revenue of ¥361.12B (+4.0% YoY) and segment profit of ¥21.29B (+0.6%). Although it is the largest segment, accounting for 58.3% of consolidated operating income, its profit growth rate fell below sales growth and its profit margin declined by approximately 20bp. The Discount Store Business reported revenue of ¥274.59B (+7.1%) and segment profit of ¥15.25B (+11.7%), exceeding the Drugstore Business in both revenue and profit growth, while its profit margin also improved by approximately 22bp. Overall earnings growth is supported by operating leverage from the expansion of the Discount Store Business, while the recovery of profitability in the core Drugstore Business will be a key focus going forward.

Key Financial Metrics

【Profitability】The operating margin was 5.7% and the net profit margin was 3.8%. Compared with the same period of the previous year, the net profit margin declined by approximately 14bp and the operating margin declined by approximately 2bp, both representing only modest changes. ROE was 8.7%, decomposed into a net profit margin of 3.8% × total asset turnover of 1.35x × financial leverage of 1.69x, indicating a conservative capital structure that maintains low leverage.【Cash Flow Quality】While profit before tax increased by +5.8% YoY, the rise in the effective tax rate to 32.6% was the primary factor behind the slowdown in net income growth; underlying profitability at the operating level remains stable.【Investment Efficiency】Total asset turnover was 1.35x, and goodwill was ¥1.35B, representing only 0.3% of total assets, indicating a low degree of reliance on intangible assets.【Financial Soundness】The equity ratio was 59.3%. Against interest-bearing debt of ¥43.96B, the Company held cash and deposits of ¥70.02B, resulting in net cash of approximately ¥26.06B. The current ratio was approximately 172%; against interest expense of ¥0.26B, operating income was ¥36.54B, indicating an extremely light interest burden.

Cash Flow Analysis

As detailed figures from the statement of cash flows are not included in the disclosed data, cash trends are analyzed based on changes in the balance sheet. Cash and deposits increased to ¥70.02B from ¥65.00B in the previous year, while retained earnings accumulated to ¥272.70B. Inventories increased to ¥110.69B from ¥98.41B in the previous year, potentially placing pressure on working capital. Meanwhile, accounts payable also increased to ¥87.62B from ¥79.73B, indicating that the Company is supplementing its funding position through the use of trade payables. Long-term borrowings increased to ¥41.46B and appear to have been allocated to funding store investments and other purposes. Overall, on-hand liquidity has increased, but the fact that inventory growth is outpacing revenue growth warrants attention from the perspective of working capital efficiency.

Quality of Earnings

The divergence between ordinary income and net income was attributable to the difference between profit before tax and income taxes and other taxes. Income taxes and other taxes of ¥11.73B were recorded against profit before tax of ¥35.96B, resulting in an effective tax rate of 32.6%, up from the previous year. Non-operating income and expenses comprised income of ¥0.75B and expenses of ¥1.09B, including interest expense of ¥0.26B, resulting in a net expense of ¥0.34B; the impact on recurring earning power was small. Extraordinary items resulted in a net loss of ¥0.24B, including non-recurring items such as impairment losses of ¥0.12B and losses on disposal of property, plant and equipment of ¥0.16B. However, their scale was limited and did not materially impair earnings quality. Comprehensive income was ¥24.24B, nearly equal to net income of ¥24.23B, indicating that the impact of accrual-related items such as valuation differences on other securities and adjustments for retirement benefits was immaterial. Accordingly, the fluctuation in net income for the period was primarily due to the increase in the tax burden, while earnings power derived from operating activities can be assessed as generally stable.

Earnings Forecast and Guidance

Progress against the full-year Company forecast was 74.8% for revenue, 77.2% for operating income, 78.7% for ordinary income, and 76.4% for net income. All were slightly above the standard Q3 progress rate of 75%. To achieve full-year operating income of ¥47.30B, ¥10.76B will be required in Q4, while ¥7.47B will be required in Q4 to achieve full-year net income of ¥31.70B. The cumulative earnings growth trend supports achievement of the full-year plan, but net income has been affected by the increase in the tax burden; the effective tax rate trend in Q4 will determine the likelihood of achieving the plan.

Shareholder Returns

The Q2 dividend was ¥65.00 per share, while the full-year Company forecast is for an annual dividend of ¥131.00 per share. The payout ratio against cumulative Q3 net income of ¥24.23B was 32.0% (calculated by dividing dividends alone by net income), whereas the forecast payout ratio based on forecast EPS of ¥271.03 and an annual dividend of ¥131.00 was approximately 48.3%. Retained earnings were substantial at ¥272.70B. Against a financial foundation comprising an equity ratio of 59.3% and net cash of approximately ¥26.06B, the sustainability of the dividend funding base is considered secure.

Risk Factors

1. Deterioration in inventory efficiency: Inventories expanded to ¥110.69B, an increase of +12.5% from ¥98.41B in the previous year. This is outpacing the +5.3% increase in revenue, and inventory turnover days are at a level exceeding 60 days on an annualized basis. There is a risk of pressure on the gross margin from slow-moving inventory and markdown sales.

2. Decline in margins in the core Drugstore Business: The segment profit margin declined by approximately 20bp from 6.09% in the previous year to 5.89%, while segment profit growth was limited to +0.6% against revenue growth of +4.0%. If profitability in this business, which accounts for 58.3% of consolidated operating income, continues to decline, it may constrain overall earnings growth.

3. Slowdown in net income growth due to the higher effective tax rate: Profit before tax increased by +5.8% YoY, but net income growth was limited to +1.7% as the effective tax rate rose to 32.6%. The Company’s tax rate trend requires close monitoring to determine whether the higher rate will become structural.

Industry Benchmark (Reference, Compiled by the Company)

Industry Benchmark (retail)

Profitability and Returns

Both the operating margin and net profit margin exceed the industry median, placing the Company’s profitability in the upper tier of the industry.

Growth and Capital Efficiency

The revenue growth rate exceeds the industry median but does not reach the upper IQR of 10.3%, placing the Company between the middle and upper tiers of the industry.

※Source: Compiled by the Company

Key Takeaways from the Earnings Results

1. The Company maintained increases in revenue and earnings, and progress toward the full-year operating income plan was 77.2%, above the standard level. However, net income growth was below operating income growth, with the increase in the effective tax rate acting as a constraint on earnings growth.

2. By business, the Discount Store Business exceeded the core Drugstore Business in both growth and profitability, with revenue of +7.1% and segment profit of +11.7%. Meanwhile, the segment profit margin of the Drugstore Business declined by approximately 20bp, indicating divergent earnings trends between the businesses.

3. Inventories increased by +12.5% YoY, expanding at a pace above revenue growth. Trends in inventory efficiency will be an important area to monitor, as they will influence the future gross margin and working capital efficiency.

Theoretical Stock Price (Reference Value)

Sensitivity: ¥2,477–¥2,620 at ±1% for the cost of equity, and ¥2,543–¥2,552 at ±0.1 for ω.

Notes:

• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).
• As net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest Rate Reference Month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting a professional advisor as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

Sandrug delivered a solid FY2026 Q3 cumulative operating performance, with sales growth sustained across both reported retail formats while net-income growth lagged because of a higher tax burden and larger net non-operating expense. Revenue increased 5.3% year on year to ¥635.7bn. Operating income rose 4.9% to ¥36.5bn, broadly tracking sales growth but modestly underperforming it. Ordinary income increased 5.4% to ¥36.2bn. Net income attributable to owners rose only 1.7% to ¥24.2bn, materially slower than operating and pre-tax profit growth. Gross profit expanded 6.2% to ¥162.9bn, ahead of sales growth. Gross margin improved by approximately 20bp year on year to 25.6%, indicating favorable merchandise mix, procurement, or pricing effects. However, SG&A expenses rose 6.5%, faster than revenue growth. As a result, the SG&A ratio increased by about 23bp to 19.9%. The operating margin therefore compressed slightly by roughly 2bp to 5.7%. The drugstore business remained the core business by operating-income contribution, generating ¥21.3bn of segment profit. The discount-store business was the faster-growing and higher-margin segment, with segment profit increasing 11.7% year on year to ¥15.3bn. Annualized ROE was 11.6%, a good level under the stated benchmark, supported by efficient asset utilization and moderate leverage. Balance-sheet liquidity remains sound, with a 172.4% current ratio, cash of ¥70.0bn, and only ¥2.5bn of short-term loans. The principal operating issue is inventory discipline: annualized inventory days of 64 exceed the 60-day warning threshold, raising markdown and cash-conversion risk if sell-through weakens. Full-year guidance appears achievable, as Q3 cumulative sales have reached 74.8% of the annual plan and operating income has reached 77.2%.

Profitability Analysis

The annualized DuPont decomposition is net profit margin of 3.8% × asset turnover of 1.803x × financial leverage of 1.69x, producing annualized ROE of 11.6%. Asset turnover is the principal contributor to the return profile, consistent with a high-volume retail model, while leverage is moderate rather than aggressive. The net margin remains structurally low relative to broad-market profitability benchmarks, but is consistent with the economics of drugstore and discount retailing. Gross margin improved to 25.6% from approximately 25.4% in the prior-year period, a gain of around 20bp. The improvement in gross profit was more than offset at the operating level by SG&A growth of 6.5%, compared with 5.3% sales growth. Consequently, operating margin declined marginally to 5.7% from approximately 5.8%. This is a limited compression rather than a material deterioration, but it indicates that cost control must improve for gross-margin gains to translate more fully into operating-profit expansion. The five-factor analysis shows a tax burden of 0.674, below the 0.70 normal reference point, explaining much of the gap between 5.8% EBIT margin and 3.8% net margin. Interest burden remains very strong at 0.984, and interest coverage of 141.1x confirms that financing cost is not a constraint. The drugstore segment generated external sales of ¥361.1bn, up 4.0% year on year, and segment profit of ¥21.3bn, up 0.6%; its segment margin was 5.2%, down from 5.4%. The discount-store segment generated external sales of ¥274.6bn, up 7.1%, and segment profit of ¥15.3bn, up 11.7%; its segment margin expanded to 5.6% from 5.3%. The higher-growth discount-store operation is therefore the current marginal driver of consolidated profit growth, although the larger drugstore operation remains the core business.

Growth Assessment

Top-line growth of 5.3% was balanced across the two operating segments, with discount stores growing faster at 7.1% and drugstores growing 4.0%. The discount-store segment's combination of faster sales growth and margin expansion suggests favorable operating leverage and/or stronger merchandise economics. Drugstore segment profit grew only 0.6%, substantially behind its 4.0% sales growth, making margin recovery in the core business important for the next stage of earnings growth. Consolidated gross profit grew 6.2%, ahead of revenue, which supports the underlying quality of sales growth. Consolidated operating income growth of 4.9% was slightly below sales growth because of SG&A deleverage. Full-year company guidance calls for sales of ¥850.0bn, operating income of ¥47.3bn, ordinary income of ¥46.0bn, and net income attributable to owners of ¥31.7bn. Q3 cumulative progress is 74.8% for sales, 77.2% for operating income, 78.7% for ordinary income, and 76.4% for net income. Against the standard 75% Q3 progress rate, operating income is 2.2 percentage points ahead and ordinary income is 3.7 percentage points ahead, while sales are essentially on schedule. This positioning supports the attainability of the current annual earnings plan, provided fourth-quarter store demand and inventory sell-through remain stable. The annual plan implies 6.0% sales growth and 6.3% operating-income growth, requiring a modest acceleration in sales growth but no major change in profitability trajectory.

Financial Health

Financial health is sound. The current ratio is 172.4%, well above the 1.0x warning threshold, and working capital is ¥99.8bn. The quick ratio is 92.1%, below 1.0x, but the shortfall is modest and is typical of inventory-based retail operations with substantial trade payables. Cash and deposits of ¥70.0bn are equivalent to 28.0x short-term loans of ¥2.5bn, substantially reducing near-term refinancing risk. Current assets of ¥237.6bn comfortably exceed current liabilities of ¥137.8bn. Interest-bearing debt totals ¥44.0bn, comprising ¥2.5bn of short-term loans and ¥41.5bn of long-term loans. Only 5.7% of interest-bearing debt is short term, so there is no material maturity mismatch between short-term funding and current assets. Debt-to-equity is a conservative 0.69x, well below the 2.0x risk threshold. Debt-to-capital is 13.6%, also indicating a restrained debt burden. Interest coverage of 141.1x provides a substantial earnings buffer against higher funding costs. Equity increased to ¥278.8bn from ¥269.7bn a year earlier, primarily reinforcing internal capital capacity. Short-term loans increased 150.0% year on year to ¥2.5bn from ¥1.0bn; the root cause appears to be an incremental use of short-term funding, but the absolute amount is immaterial relative to cash, working capital, and total debt. In retail, short-term borrowings can be used flexibly for seasonal procurement or working-capital timing; nonetheless, the movement should be monitored if it continues alongside inventory growth. Asset retirement obligations of ¥7.1bn represent store-related restoration obligations and should be considered part of the fixed-cost and network-management profile.

Notable B/S Changes

Short-term loans: +¥1.5bn (+150.0%) to ¥2.5bn — significant percentage increase, but absolute exposure remains low relative to ¥70.0bn cash and carries limited liquidity risk.

Cash Flow Quality

The operating assessment centers on working-capital discipline. Inventories increased 12.5% year on year to ¥110.7bn, materially faster than sales growth of 5.3%. Annualized inventory days are 64 days, above the 60-day warning threshold. The root cause is that inventory has accumulated faster than revenue, which may reflect assortment expansion, procurement timing, store-network needs, or slower sell-through. This level is above the typical 30-45 day general-retail reference range and also above the 45-60 day range generally associated with more durable merchandise. The impact is a higher risk of markdowns, inventory writedowns, and weaker cash conversion if consumer demand softens or product rotation slows. Inventory represents 23.5% of total assets, making stock productivity a material determinant of capital efficiency. Trade payables of ¥87.6bn exceed trade receivables of ¥32.9bn, which is consistent with a favorable supplier-financed retail working-capital model. The company should demonstrate that elevated inventory supports sales availability and growth rather than reflecting excess or aging stock.

Dividend Sustainability

The disclosed interim dividend is ¥65.0 per share. The full-year forecast dividend is ¥131.0 per share, implying a forecast dividend payout ratio of approximately 48.3% based on forecast EPS of ¥271.03. This is below the 60% sustainability reference point and leaves a meaningful earnings retention buffer. The disclosed cumulative payout ratio associated with the ¥65.0 interim dividend is 32.0% of FY2026 Q3 cumulative net income. Retained earnings total ¥272.7bn, providing substantial balance-sheet support for ordinary shareholder distributions. Conservative debt metrics, strong interest coverage, and positive working capital further support dividend capacity. Dividend sustainability will depend primarily on maintaining operating-profit growth and avoiding a material inventory-related margin reset.

Risk Assessment

Business risks include Inventory and markdown risk: annualized inventory days are 64, above the 60-day warning level, while inventories rose 12.5% year on year versus 5.3% sales growth. A deterioration in sell-through could require promotions or writedowns and pressure gross margin., Core drugstore margin risk: drugstore segment sales increased 4.0%, but segment profit increased only 0.6%, reducing its segment margin to 5.2% from 5.4%. This is important because drugstores remain the largest contributor to segment profit., Japanese retail demand and competitive risk: drugstore and discount formats are exposed to consumer spending conditions, price competition, promotional intensity, and changes in product mix. These factors can quickly affect traffic, basket size, and gross margin., Labor and store-cost inflation risk: SG&A grew 6.5%, faster than sales, producing approximately 23bp SG&A-ratio deleverage. Persistent wage, utility, logistics, or occupancy cost increases would constrain operating leverage..

Financial risks include Funding-cost risk is currently limited but should be monitored because long-term loans total ¥41.5bn and interest expense increased to ¥2.6bn from ¥1.0bn in the prior-year period., Short-term loans increased 150.0% year on year to ¥2.5bn. The absolute exposure is small and well covered by cash, but repeated increases could signal greater reliance on short-term funding..

Key concerns include The highest-priority concern is inventory productivity, given the combination of 64 inventory days and inventory growth that exceeds sales growth., The second priority is restoring operating leverage in the drugstore segment, where profit growth materially lags sales growth., Net income growth of 1.7% trails operating-income growth of 4.9%, reflecting the higher effective tax rate of 32.6% and limiting conversion of operating gains into shareholder earnings..

Investment Implications

Key takeaways include Sales and operating profit are progressing in line with, or modestly ahead of, the full-year plan at the Q3 stage., The discount-store segment is the faster-growing and higher-margin earnings driver, while drugstore profitability requires attention., Annualized ROE of 11.6%, a 172.4% current ratio, 0.69x debt-to-equity, and 141.1x interest coverage indicate a balanced return and risk profile., Inventory days of 64 are the central operating metric to monitor because they create potential pressure on cash conversion and markdown risk., Forecast dividend payout of approximately 48.3% appears compatible with earnings, retained earnings, and the current capital structure..

Metrics to watch include Drugstore segment profit growth and segment margin, Discount-store segment sales growth and segment margin, Annualized inventory days and inventory growth relative to sales growth, Gross margin and SG&A ratio, Fourth-quarter sales and operating-income delivery versus the ¥850.0bn and ¥47.3bn full-year plans, Short-term loan balance and interest expense.

Regarding relative positioning, Sandrug exhibits the profile of a financially conservative, high-turnover Japanese retailer: operating margins are modest but gross margin is within the general-retail benchmark range, annualized ROE is good at 11.6%, and leverage is moderate. Its current differentiation is stronger momentum in discount stores, whereas the near-term constraint is inventory intensity and modest SG&A deleverage in the larger drugstore business.